A detailed history of Quadrant Capital Group LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,471 shares of SUPN stock, worth $50,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,471
Previous 2,288 35.71%
Holding current value
$50,234
Previous $78,000 50.0%
% of portfolio
0.0%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$25.99 - $33.85 $21,233 - $27,655
-817 Reduced 35.71%
1,471 $39,000
Q1 2024

May 15, 2024

BUY
$27.11 - $35.17 $22,745 - $29,507
839 Added 57.9%
2,288 $78,000
Q4 2023

Feb 08, 2024

BUY
$22.72 - $29.68 $30,217 - $39,474
1,330 Added 1117.65%
1,449 $41,000
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $5,183 - $6,187
-188 Reduced 61.24%
119 $3,000
Q2 2023

Aug 09, 2023

BUY
$29.91 - $38.73 $1,136 - $1,471
38 Added 14.13%
307 $9,000
Q1 2023

May 11, 2023

BUY
$34.93 - $42.03 $3,493 - $4,203
100 Added 59.17%
269 $9,000
Q4 2022

Feb 10, 2023

SELL
$31.09 - $37.88 $11,596 - $14,129
-373 Reduced 68.82%
169 $6,000
Q3 2022

Nov 10, 2022

BUY
$28.79 - $35.41 $11,516 - $14,163
400 Added 281.69%
542 $18,000
Q2 2022

Aug 09, 2022

BUY
$25.33 - $34.25 $329 - $445
13 Added 10.08%
142 $4,000
Q4 2021

Feb 01, 2022

SELL
$26.37 - $34.22 $553 - $718
-21 Reduced 14.0%
129 $4,000
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $329 - $439
14 Added 10.29%
150 $4,000
Q2 2021

Aug 09, 2021

BUY
$26.72 - $33.19 $187 - $232
7 Added 5.43%
136 $4,000
Q4 2020

Feb 16, 2021

BUY
$17.7 - $25.81 $371 - $542
21 Added 19.44%
129 $3,000
Q1 2020

May 15, 2020

BUY
$14.45 - $24.69 $679 - $1,160
47 Added 77.05%
108 $2,000
Q3 2019

Oct 24, 2019

SELL
$25.47 - $33.37 $20,299 - $26,595
-797 Reduced 92.89%
61 $1,000
Q2 2019

Jul 24, 2019

BUY
$29.96 - $38.87 $23,878 - $30,979
797 Added 1306.56%
858 $28,000
Q3 2018

Oct 29, 2018

SELL
$42.7 - $56.55 $1,622 - $2,148
-38 Reduced 38.38%
61 $3,000
Q2 2018

Aug 09, 2018

BUY
$44.1 - $59.85 $1,675 - $2,274
38 Added 62.3%
99 $5,000
Q1 2018

May 10, 2018

SELL
$37.15 - $46.9 $1,597 - $2,016
-43 Reduced 41.35%
61 $2,000
Q3 2017

Oct 13, 2017

BUY
$36.75 - $49.65 $1,580 - $2,134
43 Added 70.49%
104 $3,000
Q2 2017

Aug 15, 2017

BUY
N/A
61
61 $0

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.83B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.